Esperion Therapeutics (ESPR) Inventory Average (2020 - 2025)
Esperion Therapeutics (ESPR) has disclosed Inventory Average for 6 consecutive years, with $106.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Inventory Average rose 22.38% year-over-year to $106.8 million, compared with a TTM value of $106.8 million through Dec 2025, up 22.38%, and an annual FY2025 reading of $99.8 million, up 24.67% over the prior year.
- Inventory Average was $106.8 million for Q4 2025 at Esperion Therapeutics, down from $111.5 million in the prior quarter.
- Across five years, Inventory Average topped out at $111.5 million in Q3 2025 and bottomed at $18.1 million in Q1 2021.
- Average Inventory Average over 5 years is $57.9 million, with a median of $45.5 million recorded in 2023.
- The sharpest move saw Inventory Average surged 333.58% in 2021, then decreased 5.3% in 2022.
- Year by year, Inventory Average stood at $34.2 million in 2021, then fell by 5.3% to $32.4 million in 2022, then soared by 80.8% to $58.5 million in 2023, then skyrocketed by 49.15% to $87.3 million in 2024, then grew by 22.38% to $106.8 million in 2025.
- Business Quant data shows Inventory Average for ESPR at $106.8 million in Q4 2025, $111.5 million in Q3 2025, and $106.9 million in Q2 2025.